CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diabetes and other diseases characterized by organ-specific cell damage, today presented preliminary data highlighting the potential of the Company's unique cell-based therapy for treating diabetes at the 7th Annual New York Stem Cell Summit. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, provided an overview of the Company's Pathfinder Cell ("PC") technology, and presented preclinical evidence demonstrating how treatment with PCs was able to reverse the symptoms of diabetes in two different mouse models.

Pathfinder Cells are a newly identified non-stem cell mammalian cell type that has the ability to stimulate regeneration of damaged tissue without being incorporated into the new tissue. In today's presentation, Dr. Franklin showed how recent experiments performed using a non-obese diabetic (NOD) mouse strain were supportive of earlier data that demonstrated complete reversal of diabetes in mice. The earlier results, which used a drug-induced diabetic mouse model, were published in Rejuvenation Research1. Though preliminary, the recent results are encouraging because the NOD mouse model is widely used and highly regarded as being predictive of human type-1 diabetes.

In three separate experiments using this model, 30-50% of the mice treated with PCs at the onset of diabetes returned to normal blood glucose levels. Of the mice that responded well to treatment, the effects tended to be long lasting, up to two months in some cases after just two doses. These results, which were generated by intravenous injection of PC's derived from rat pancreatic tissue, further demonstrate the remarkable ability of Pathfinder Cells to elicit their positive effect regardless of the organ, or even species, of origin.

"We are very encouraged by these preclinical results using NOD mice. This model is the gold standard for type-1 diabetes and the fact that recent experiments mirror what we've seen in previous models may be highly significant," stated Dr. Franklin. "We have many questions to answer about how PCs act in the body, but we believe, based on previous experiments, that PCs may stimulate regeneration of damaged islet cells that produce insulin. The current NOD mouse data also suggest that PCs may have an effect in modulating the auto-immune process in type 1 diabetes. We continue to conduct experiments aimed at elucidating the optimal dosing and other factors that may be responsible for producing a robust and long-lasting response, as this will be critical as we start to think about how PCs may be used in treating human diabetes."

In his presentation today, Dr. Franklin also provided further insight into the mechanism of action of PCs, based on recent animal experiments. It was observed previously that PCs produce microvesicles, which are known to play a role in intercellular communication, but through mechanisms that are poorly understood. In a recent experiment, Pathfinder was able to isolate these microvesicles from the PCs and treat animals directly with an injection containing microvesicles only. Remarkably, both PC- and microvesicle-treated mice exhibited similar reductions in blood glucose compared to controls using the same drug-induced diabetes mouse model. This suggests, not only that the microvesicles produced by PCs are central to the mechanism of action, but that the microvesicles alone appear to be sufficient to produce the full effect.

Dr. Franklin commented, "If confirmed, this finding could have a significant positive impact on the future of PC-based therapy. Due to the relatively small amount of material contained within the microvesicles, determining the specific factor(s) that are responsible for regenerating damaged tissue could be more straightforward than we first anticipated, bringing us closer to understanding the mechanism of action. There may also be a number of potential manufacturing and storage benefits to using microvesicles versus PCs that will be interesting to explore in parallel as we work to advance this innovative new therapeutic approach closer to human clinical development."

The New York Stem Cell Summit brings together cell therapy company executives, researchers, investors and physicians to explore investment opportunities in cell therapy research and innovation. More information can be found at http://www.stemcellsummit.com.

Presentation details Event: 7th Annual New York Stem Cell Summit Date: Tuesday, February 21, 2012 Place: Bridgewaters New York, 11 Fulton Street, New York, NY Time: 3:35 pm ET

About Pathfinder

Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells ("PCs") Pathfinder is pioneering a new field in regenerative medicine.

PCs are a newly identified mammalian cell type present in very low quantities in a variety of organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood. Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue. Based on testing to date, the cells appear to be "immune privileged," and their effects appear to be independent of the tissue source of PCs. For more information please visit: http://www.pathfindercelltherapy.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to obtain additional required financing; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results, if any; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; technological changes; and government regulation. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

1Karen Stevenson, Daxin Chen, Alan MacIntyre, Liane M McGlynn, Paul Montague, Rawiya Charif, Murali Subramaniam, W.D. George, Anthony P. Payne, R. Wayne Davies, Anthony Dorling, and Paul G. Shiels. Rejuvenation Research. April 2011, 14(2): 163-171. doi:10.1089/rej.2010.1099

See the original post:
Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

27-01-2012 00:12 Mouse embryonic stem cells were coaxed into becoming heart cells. Protocol adapted from Maltsev et al 1993. The cells can be seen beating under low magnification. Sweet!

See original here:
Stem cells becoming heart cells - Video

08-02-2012 01:41 A UCSF stem cell study conducted in mice suggests a novel strategy for treating damaged cardiac tissue in patients following a heart attack. The approach potentially could improve cardiac function, minimize scar size, lead to the development of new blood vessels -- and avoid the risk of tissue rejection. In the investigation, reported online in the journal PLoS ONE, the researchers isolated and characterized a novel type of cardiac stem cell from the heart tissue of middle-aged mice following a heart attack. Then, in one experiment, they placed the cells in the culture dish and showed they had the ability to differentiate into cardiomyocytes, or "beating heart cells," as well as endothelial cells and smooth muscle cells, all of which make up the heart. In another, they made copies, or "clones," of the cells and engrafted them in the tissue of the mice who had had the heart attacks. The cells induced angiogenesis, or blood vessel growth, or differentiated, or specialized, into endothelial and smooth muscle cells, improving cardiac function. Because the cells were transplanted back into the mice from which they originated, the body did not reject them.

Read the original post:
Stem Cell Study in Mice Offers Hope for Treating Heart Attack Patients - Video

08-02-2012 18:24 (October 25, 2011) Associate Professor at the Stanford School of Medicine, Joseph Wu explores how stem cells may be used in the future to repair hearts that have failed. This course is a single-quarter, focused follow-up to the the yearlong Mini Med School that occurred in 2009-10. The course focuses on diseases of the heart and cardiovascular system. The course is sponsored by Stanford Continuing Studies and the Stanford Medical School. Stanford University http://www.stanford.edu Stanford Continuing Studies http:///continuingstudies.stanford.edu/ Stanford University School of Medicine med.stanford.edu Stanford University Channel on YouTube: http://www.youtube.com

Follow this link:
5. Stem Cells for Cardiac Repair | Mini Med School - Video

08-02-2012 18:45 (October 18, 2011) Associate Professor of Mechanical Engineering Beth Pruitt discusses his work in human embryonic stem-cell-derived cardiac myosites and future opportunities to use heart cells for regenerative therapy. This course is a single-quarter, focused follow-up to the the yearlong Mini Med School that occurred in 2009-10. The course focuses on diseases of the heart and cardiovascular system. The course is sponsored by Stanford Continuing Studies and the Stanford Medical School. Stanford University http://www.stanford.edu Stanford Continuing Studies http://www.continuingstudies.stanford.edu Stanford University School of Medicine http://www.med.stanford.edu Stanford University Channel on YouTube: http://www.youtube.com

Read more:
4. Bioengineering Cardiovascular Tools | Mini Med School - Video

09-01-2012 06:07 Bone marrow stem cells versus cord blood stem cells : Prof.Dr. Virginia

More:
Bone marrow stem cells versus cord blood stem cells : Prof.Dr. Virginia - Video

10-01-2012 19:46 If you match a patient you will be asked to donate stem cells from either your bloodstream or bone marrow. Learn how it's done by watching this video.

Read the original here:
PBSC vs. BONE MARROW DONATION - Video

31-01-2012 13:21 Ronald W. Hanson, Jr., MD lectures at the 11th Clinical Applications for Age Management Medicine in November 2011, in Las Vegas, Nevada This focused conference track cocentrated on regenerative and cell-based medicine continue to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. This track will focus on the latest developments in cell-based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. For more information contact conference@agemed.org Visit our website at agemed.org

The rest is here:
The Use of Guided Bone Marrow Nucleated Cell Fraction Injections - Ronald W. Hanson, Jr., MD - Video

05-02-2012 05:11 Dr. Martin of MetroMD performs a bone marrow extraction procedure to harvest stem cells. The extracted bone marrow will be centrifuged to separate targeted stem cells and re-injected into the patient's injured joints. Questions? Please call the MetroMD Institute of Regenerative Medicine at (323) 285-5300 or email us at info@MetroMD.net. MetroMD.net

Read the rest here:
Bone Marrow Extraction Procedure to Harvest Stem Cells | MetroMD Los Angeles - Video

05-02-2012 11:27 MetroMD.net Dr. Martin explains why bone marrow is a better source than fat tissue for viable stem cells in your own body. Questions? Please call the MetroMD Institute of Regenerative Medicine at (323) 285-5300 or email us at info@MetroMD.net. Los Angeles

See the original post:
What Is The Best Source for Stem Cells- Bone Marrow or Fat Tissue? | MetroMD Los Angeles - Video

18-01-2012 23:09 NewHopeForAging.info - Beverly Hills Plastic Surgeon, Dr. Nathan Newman reveals the truth about the Adult Stem Cell Technology...and the ONLY product on the market with it Luminesce, by Jeunesse. Order it at: NewHope.JeunesseGlobal.com or call 561.779.0000

Continued here:
Dr Newman Exposes The Truth about Adult Stem Cells - Video

20-12-2011 08:50 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

See the original post here:
Adult Stem Cell Treatments for COPD - Real patient results, USA Stem Cells - Marian H. Testimonial - Video

To: HEALTH AND NATIONAL EDITORS

VIRGINIA BEACH, Va., Feb. 20, 2012 /PRNewswire-USNewswire/ -- Rony Thomas, President and CEO of LifeNet Health, is presenting at the 7th Annual Stem Cell Summit in New York City on February 21, 2012. Mr. Thomas will be presenting on LifeNet Health's broad offerings of current and future regenerative biologic-based products. Mr. Thomas will also focus on the multiple new capabilities and technology platforms of the LifeNet Health Institute of Regenerative Medicine.

(Photo: http://photos.prnewswire.com/prnh/20120220/DC55479)

"The use of a variety of forms of donated tissues has worked for decades to save lives and restore health in many surgical disciplines. Now we are on the cusp of developing cellular therapies, tissue engineering and new medical applications for allografts to treat disease and assist in the development of lifesaving drugs. The opening of the LifeNet Health Institute of Regenerative Medicine this year will signal our commitment to future development in the cellular therapies arena," stated Mr. Thomas. Thomas will further focus on two new areas of development; Human Basement Membranes in zeno-free culture of consented Human mRNA Reprogrammed Induced Pluripotent Stem Cells and Induced Pluripotent Stem Cells (iPSc) derived using non-integrating mRNA reprogramming technology from fully consented queryable human donor banked system.

Mr. Thomas was also recently invited to and attended a White House Summit to discuss ways in which technology and innovation can drive employment opportunities for Virginia, where LifeNet Health and the Institute are located. The meeting of key CEOs with the Obama Administration was to gain insight and input on the job market and technology as a driver to local, state, and national economies. Thomas stated, "Our foray into regenerative medicine should not only impact our state and local economy, but provide medical benefits to patients and drug companies across the globe."

The annual Stem Cell Summit brings key leaders in the medical, scientific and business innovators in this growing space of technology and regenerative medicine. LifeNet Health is pleased to be joining the Summit for the first time in 2012 as they look for key partnerships and collaboration in the discovery of cell-based therapies for a broad spectrum of medical applications in orthopedics, trauma, dental, craniomaxillofacial (CMF), plastics, and cardiovascular surgery.

LifeNet Health helps to save lives and restore health for thousands of patients each year. We are the world's most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies--a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.

The LifeNet Health Institute of Regenerative Medicine is a division of LifeNet Health located in Virginia Beach, Virginia. The Institute's labs will be expanding as new facilities are under construction and planned to be completed in the fall of 2012. Once completed and fully functional, the Institute will house over 50 medical, scientific, and research staff members. The focus will be on the science of developing regenerative medicine products for patients all over the world, and will serve as a global center of excellence for research and development focused on cellular therapies, tissue engineering, and new medical applications for allografts to maximize the gift of donation.

SOURCE LifeNet Health

-0-

See the rest here:
LifeNet Health is Presenting at the 7th Annual Stem Cell Summit in New York on February 21, 2012

The day – Valentine’s Day, as it happened – began in a whirl of coffee cups, bustling dogs and homework, then a brisk walk around the block – in other words, business as usual for a UC Irvine couple who are a high-profile science team engaged in cutting-edge stem-cell research.

Brian Cummings and Aileen Anderson, whose stem-cell treatment for spinal cord injury is being tested on patients in Switzerland, say their office – only a short walk from their home on the UCI campus – has a family feel as well.

At UCI’s recently constructed Stem Cell Research Center, they supervise a crew of young students and technicians whose bond with their mentors is so close that they call themselves the “Andermings.”

“I suppose it’s like having an orphanage,” Cummings joked as he prepared for the day ahead.

It would include a lengthy meeting with the Andermings on how best to grow human embryonic stem cells without animal-cell contamination, a critique of a doctoral candidate’s presentation of potentially significant new findings and a session with Alzheimer’s researchers at an institute called UCI MIND.

But first, Cummings, Anderson and their two dogs – Chesapeake and Indiana – had to get the couple’s 6-year-old daughter, Camryn, to school.

After Camryn finished her homework (completed strategically a day in advance, leaving more time for afternoon play), they took the long way round to the Montessori school, also easy walking distance from their home.

Along the way, they encountered another faculty couple, from the German department, and their dog. They stopped with Camryn, giggling as the dogs rolled and tumbled on a neighbor’s lawn.

•••

Cummings, 47, and Anderson, 45, together since they were both undergrads at the University of Illinois, say living and working with each other comes naturally.

“People say, ‘Do I need a break from her?’ ” Cummings said as he wrangled the dogs.

“More people say, ‘Do you need a break from him?’ ” Anderson replied.

Later, the conversation transitions into a science meeting as the two take the 20-minute walk past UCI’s Ecological Preserve and into the Sue and Bill Gross Stem Cell Research Center. The energy-efficient building, with an open design to encourage chance meetings among scientists, houses a roster of high-powered researchers as well as their experimental subjects: rodents.

The center was seeded by $27 million in state stem-cell funding and $10 million from donors Bill and Sue Gross. The building was completed in 2010.

Now, researchers working there cultivate lines of human embryonic stem cells that can grow into a variety of cell types, from brain cells to liver and heart cells.

The ability to coax stem cells into many forms – and with it the potential to treat Alzheimer’s, paralysis and a long list of diseases – is fueling an explosion of research around the nation and across the state.

Anderson and Cummings showed that their stem-cell treatment, using cells derived from aborted fetuses, allowed partially paralyzed rats to walk again. The rat’s recovery was revealed in a dramatic before-and-after video.

So far, the human trial of the treatment in Switzerland is showing no ill effects on patients, Cummings said.

But stem-cell research is buffeted by political controversy, funding uncertainties and, sometimes, attacks by stem-cell research opponents.

The trial of the treatment developed by Cummings and Anderson with their collaborators, StemCells Inc., was the first of its kind in the world when it was announced in 2010.

In some ways, that made the family – and their team – a target.

Concerns about possible intruders prompted the couple to place a camera at their front door. Cummings’ tires have been slashed, he said, though he doesn’t know if that was the work of people who oppose the harvesting of human embryonic stem cells, animal-rights activists (angered by experiments on rodents) or perhaps a disgruntled student.

At the moment, Cummings and Anderson are running five research programs and leading 17 researchers. All of it is funded by $2.2 million in grants, much of it from California Institute for Regenerative Medicine, or CIRM.

Created by voter initiative – Proposition 71 in 2004 – CIRM is California’s $3 billion answer to federal restrictions on funding for stem-cell research. Those restrictions were started by the Bush administration and eased, but not eliminated, under President Obama.

Cummings said opposition to their research is based, in part, on incorrect assumptions.

A big one is that the research involves the destruction of embryos. In reality, they work with balls of cells created at an earlier stage of human development, called blastocysts – a distinction many opponents do not draw.

“Embryonic stem cells don’t come from embryos,” he said. “And they never have.”

The raw material comes from fertility clinics and otherwise would be discarded.

Cummings says those who say that such research is immoral have it wrong.

“The argument is backward,” he said. “It’s immoral to throw away this stuff and not use it to help someone.”

••

During their meeting with the Andermings, project leader Hal Nguyen described the group’s plan to grow a series of stem-cell cultures and check a compelling question: Is some of a stem cell’s transformation guided by the microscopic environment in which it dwells, or is it entirely dictated by the cell’s internal workings?

“The plan is in the email,” Nguyen told Anderson.

“Dude, I have 400 emails,” Anderson said.

The group’s task was meant to answer a classic nature-nurture question, Anderson said. In this case, “nature” is the DNA coding in the stem cell itself, while “nurture” is the cellular environment, with all its floating nutrients and chemical signals.

“Will that environment, the extrinsic factor, trump anything the cell can do?” Anderson had wondered earlier. “Or is the intrinsic programming of the cell the principal determinant? Is that the main driving factor?”

Cummings stood by in the tiny meeting room while the researchers batted around their questions and answers. He said Anderson, a spinal cord specialist, was the expert in this arena, though he couldn’t help piping in during a discussion of the medium in which the cells would be grown.

“You’re comparing two different medias, too?” Cummings asked.

“We all know what we’re talking about,” Anderson told him. “Don’t interrupt.”

Then it was on to a larger, mostly empty meeting room where Sheri Peterson, a doctoral candidate, wanted to test her presentation on Cummings and Anderson.

Her eventual target is an advancement committee that will determine her future. The presentation will be crucial in her quest for a Ph.D.

Peterson ran through an array of slides projected on a large screen to reveal her findings. Inflammation of damaged tissue being regenerated in rats, she said, might be eased or worsened simply by manipulating proteins surrounding the regenerating cells.

Again, the topic was in Anderson’s wheelhouse.

“My notes said, ‘Nicely done,’ ” Cummings told Peterson.

“He’s not an aficionado,” Anderson said.

The husband-and-wife researchers then provided her with a detailed, slide-by-slide critique.

•••

Cummings’ expertise centers on traumatic brain injury. But he also is an expert at the complex task of marshaling grant funding. On his office wall, a whiteboard densely covered with writing tells the story: Cummings must police incoming and outgoing grants like an air traffic controller, timing the grants and the work they fund to match years of employment for graduate students and staff members.

The grants come and go over months and years, and so do the students and staff. Get the timing wrong, and you might have funding with no researchers, or researchers with nothing to do.

“At UCI, I’m like a small-business owner,” Cummings said.

Over a hasty lunch in his office (cold sandwiches grabbed during a trip, with Anderson, to a nearby campus snack shop), Cummings spoke of the merging of home and office life.

Writing up grant requests takes up both researchers’ time. Often, as they write, Camryn is playing in the background, whether at home or at the office. And research collaborators can show up wanting to conduct interviews at any time, holidays included.

“I did draw a line in the sand at Christmas Eve,” Anderson said.

Cummings knows such stress has driven other husband-and-wife teams into open conflict. But that just isn’t his and Anderson’s style. In fact, he said, keeping a scientific perspective, even at home, might help keep things calm.

“There’s no need to be yelling and shouting at each other because we don’t think that way,” he said. “You’re supposed to believe nothing until you prove it.”

That doesn’t mean they don’t differ, sometimes strongly, over scientific details.

“They don’t always agree with each other, and that’s good,” said Brittany Greer, an intern in their lab and an Anderming.

Nurturing the students and young scientists is part of the pleasure of doing science for both halves of the research couple, Anderson said.

“You start to look at this crowd of people as your second family,” she said. “They’re your kids. That is fun and rewarding for sure.”

You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.

Continue reading here:
Stem-cell scientists find right chemistry

WFMY News 2

Wake Forest Biotech Place Will House Hundreds of Medical Researchers WFMY News 2 Biotechnology and medical research is helping that happen. Wake Forest Biotech Place opens Tuesday in Piedmont Triad Research Park. It's called a state-of-the-art, world-class, 242000 square-foot, biotechnology research and innovation center. and more »

Source:
http://news.google.com/news?q=biotechnology&output=rss

Ghana Business News

Ghana's Biosafety Law finally receives Presidential Assent BusinessGhana The Law, from the Biosafety Act, 831, 2011 will enable Ghana to allow the application of biotechnology in food crop production involving Genetically Modified Organisms (GMOs) to enter food production. It will also ensure an adequate level of production ... Ghana Now Has Biosafety LawPeace FM Online all 5 news articles »

Source:
http://news.google.com/news?q=biotechnology&output=rss

Talk of the Sound

Sound Shore Medical Center Resident Receives Young Scientist Award Talk of the Sound Recently, she was in Barcelona, Spain to attend the World Congress on Debates & Consensus in Bone, Muscle & Joint Diseases where she presented her Abstract, “Molecular Genetics in the Diagnosis of Calpainopathy”. Even more impressive, Dr. Poste ...

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

Via Scoop.it – inPharmatics
Privacy controlled & safe social network for Healthcare launched by Jonathan Schwartz, Ex-CEO Sun Microsystems. The networks available at http://www.carezone.com  Connects Caregivers With family members and allows health-care workers share information about aging or ill parents, spouses and children
Via http://www.bloomberg.com

Source:
http://microarray.wordpress.com/feed/

Source:
http://microarray.wordpress.com/feed/

The mainstream media waxed enthusiastic last month when a California hESC clinical trial reported positive results dealing with blindness.

The report was first published account of a human trial of embryonic stem cell based therapy and involved Advanced Cell Technology, which is headquartered in Santa Monica, Ca. Despite a glowing reception of the trial's results, the firm is years away from being able to market the therapy at a profit – if it ever can do so.

The firm's chief scientific officer, Robert Lanza, moved quickly, however, to capture some monetary gain from the news, which was announced in a press release Jan. 23 by ACT.

On Jan. 23 and 24, Lanza sold 7.7 million shares in ACT for $1.5 million, according to SEC documents. He sold the stock at 18 and 19 cents a share. That compares to an ACT price of about 8 cents at the end of 2011. Lanza still holds 26 million shares in the firm. The acquisition price of the stocks is unknown.

There is nothing to suggest anything untoward about Lanza's sale. But it is a reminder that creating a successful stem cell therapy is about making money. Without a profit, there will be no therapy, as Geron reminded everyone last November when it dropped its longstanding hESC trial.

The California Stem Cell Report has asked Lanza if he has any comments about the sale of the stock. We will carry his remarks verbatim when we receive them.

The Seeking Alpha web site appears to have been the first to report the sale. Here is their complete item.

"Advanced Cell Technology, Inc. (ACTC.OB): ACTC is a development-stage biotech focused on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. On Wednesday, Chief Science Officer Robert Lanza filed SEC Form 4 indicating that he sold 7.7 million shares for $1.5 million, ending with 26.0 million shares after that sale. ACTC shares have rallied strongly since the beginning of the year, up from 8.2 cents at the end of last year to currently in 14-15c range after rising above 20c just earlier this week."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss